Bayer/MSD Verixiguat Approved in China to Treat Heart Failure
On May 19, the official website of China’s National Medical Products Administration (NMPA) announced that the innovative therapy vericiguat (Verquvo) jointly developed by Bayer and Merck & Co. (MSD) has been approved by priority review. Marketed for symptomatic chronic heart failure in stable adult patients with reduced ejection fraction (ejection fraction <45%) after recent heart failure decompensated intravenous therapy to reduce the risk of hospitalization for heart failure or the need for emergency IV diuretics risks of treatment.
Vericiguat is a soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels by directly stimulating sGC, thereby relaxing smooth muscle and dilating blood vessels. The launch of this drug provides a new treatment option for adult patients with symptomatic chronic heart failure.
You May Interested In
2026-10-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
Bayer Wins Big on Roundup
-
Glyphosate Becomes a Trade Fight
-
Bayer’s Flubendiamide Business Acquired by Tagros, Bringing a New Operator to Markets in Over 25 Countries Worldwide
-
Crystal Crop Protection Acquires Ethoxysulfuron Assets from Bayer AG
-
Bayer launches its new Fluopicolide fungicide in Brazil
-
Bayer Australia is officially certified and 60 products are produced locally
-
Bayer: Revenue of 13.765 billion euros( Q1)was in line with expectations
-
Bayer will introduce the first biocide for field crops that can effectively control coleopterans
-
Bayer degrades pesticide wastewater on farms to reduce pollution and carbon
Recommend Reading
-
![“Amputate to Survive, or Bleed to Feed the Vultures?”: Dow’s 4,500 Layoffs Reveal the Life-or-Death Battle in Global Chemicals]()
“Amputate to Survive, or Bleed to Feed the Vultures?”: Dow’s 4,500 Layoffs Reveal the Life-or-Death Battle in Global Chemicals
-
![Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness]()
Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness
-
![“Europe’s Chemical Industry Is Bleeding”: 37 Million Tons of Capacity Shut Down in 4 Years—Is the Industrial Heartbeat Failing?]()
“Europe’s Chemical Industry Is Bleeding”: 37 Million Tons of Capacity Shut Down in 4 Years—Is the Industrial Heartbeat Failing?
-
![“Hidden Champion” Swallowed Whole: PPG’s Acquisition of EMM Isn’t Just About Three Brands—It’s a Grab for the Next Decade’s Coating Authority]()
“Hidden Champion” Swallowed Whole: PPG’s Acquisition of EMM Isn’t Just About Three Brands—It’s a Grab for the Next Decade’s Coating Authority
-
![Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical Agree in Principle to Establish New Joint Venture to Restructure Ethylene Production in Western Japan]()
Asahi Kasei, Mitsui Chemicals, and Mitsubishi Chemical Agree in Principle to Establish New Joint Venture to Restructure Ethylene Production in Western Japan
-
![Multiple Positive Factors Drive Significant Increase in MTBE Market in China]()
Multiple Positive Factors Drive Significant Increase in MTBE Market in China
-
![China’s Marine Fuel Market in May Experiences Volatile Downward Trends]()
China’s Marine Fuel Market in May Experiences Volatile Downward Trends
-
![Premium Global Chemical Sourcing Requests (13-17 Oct 2025)]()
Premium Global Chemical Sourcing Requests (13-17 Oct 2025)
-
![Premium Global Chemical Sourcing Requests (26 - 29 Mar, 2026)]()
Premium Global Chemical Sourcing Requests (26 - 29 Mar, 2026)
-
![Strong Cost Support Drives PTA Prices Higher in January]()
Strong Cost Support Drives PTA Prices Higher in January
